Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer

Bookmark and Share
Published: 18 Jan 2011
Views: 5209
Rating:
Save
Prof Luca Gianni - Fondazione IRCCS Istituto Tumori di Milano, Italy

The combination of pertuzumab and trastuzumab had superior antitumor activity in women with early HER2-positive breast cancer, according to Phase II study results of the NeoSphere neoadjuvant trial.
Details of these study results were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12, 2010.